BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2021 11:08:14 AM | Browse: 760 | Download: 1995
 |
Received |
|
2021-02-24 17:54 |
|
Peer-Review Started |
|
2021-02-24 18:04 |
|
First Decision by Editorial Office Director |
|
2021-04-19 04:50 |
|
Return for Revision |
|
2021-04-19 04:50 |
|
Revised |
|
2021-05-03 15:41 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-09 03:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-09 12:04 |
|
Articles in Press |
|
2021-07-09 12:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-08-09 02:01 |
|
Publish the Manuscript Online |
|
2021-08-14 11:08 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kabsoo Shin, Eun-Kyo Jung, Se Jun Park, Sangwoon Jeong, In-Ho Kim and Myung-ah Lee |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Myung-ah Lee, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Secho-gu, Seoul 06591, South Korea. angelamd@catholic.ac.kr |
| Key Words |
Pancreatic adenocarcinoma; Serum carbohydrate antigen 19-9; Neutrophil-to-lymphocyte ratio; Multivariate analysis; Prognosis; Chemotherapy |
| Core Tip |
In pancreatic cancer patients treated with first-line chemotherapy, carbohydrate antigen 19-9 (CA19-9) decline is considered as a prognostic marker. However, there has been no consensus regarding the degree of CA19-9 decline, and certain populations show false negativity. We evaluated the cut-off value of decline of CA19-9 and post-treatment neutrophil-to-lymphocyte ratio (NLR) as prognostic makers. Combination of post-treatment NLR (< 2.62) and decline of CA19-9 (≥ 18%) for CA19-9 positive group or post-treatment NLR alone for CA19-9 negative group could be used as a prognostic marker and an adjuvant tool for response evaluation. |
| Publish Date |
2021-08-14 11:08 |
| Citation |
Shin K, Jung EK, Park SJ, Jeong S, Kim IH, Lee MA. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021; 13(8): 915-928 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i8/915.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i8.915 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
